Cite
Mowbray CE, Braillard S, Glossop PA, et al. DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. J Med Chem. 2021;64(21):16159-16176doi: 10.1021/acs.jmedchem.1c01437.
Mowbray, C. E., Braillard, S., Glossop, P. A., Whitlock, G. A., Jacobs, R. T., Speake, J., Pandi, B., Nare, B., Maes, L., Yardley, V., Freund, Y., Wall, R. J., Carvalho, S., Bello, D., Van den Kerkhof, M., Caljon, G., Gilbert, I. H., Corpas-Lopez, V., Lukac, I., Patterson, S., Zuccotto, F., & Wyllie, S. (2021). DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of medicinal chemistry, 64(21), 16159-16176. https://doi.org/10.1021/acs.jmedchem.1c01437
Mowbray, Charles E, et al. "DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis." Journal of medicinal chemistry vol. 64,21 (2021): 16159-16176. doi: https://doi.org/10.1021/acs.jmedchem.1c01437
Mowbray CE, Braillard S, Glossop PA, Whitlock GA, Jacobs RT, Speake J, Pandi B, Nare B, Maes L, Yardley V, Freund Y, Wall RJ, Carvalho S, Bello D, Van den Kerkhof M, Caljon G, Gilbert IH, Corpas-Lopez V, Lukac I, Patterson S, Zuccotto F, Wyllie S. DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. J Med Chem. 2021 Nov 11;64(21):16159-16176. doi: 10.1021/acs.jmedchem.1c01437. Epub 2021 Oct 28. PMID: 34711050; PMCID: PMC8591608.
Copy
Download .nbib